Drug facts
BrandTrelegy Ellipta (Fluticasone, Umeclidinium and Vilanterol)
No generic fluticasone, umeclidinium and vilanterol is approved; the latest Trelegy Ellipta patent or exclusivity in the Orange Book runs to 04/11/2031.
Trelegy Ellipta was first approved by the FDA on 09/18/2017 under NDA 209482; the application holder is Glaxosmithkline Intellectual Property Development Ltd England.
The latest NADAC for TRELEGY ELLIPTA 100-62.5-25 is $11.09 per unit (as of 10/28/2026).
01Patents and exclusivity
When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.
1,623days until the latest patent expires
- Latest patent
- 04/11/2031Trelegy Ellipta Orange Book
02Competition
- Generics
- No generic approved Orange Book
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
- NADAC
- $11.09 per unitTRELEGY ELLIPTA 100-62.5-25, as of 10/28/2026 CMS NADAC
04Product
- Application holder
- Glaxosmithkline Intellectual Property Development Ltd England Orange Book
- Application
- NDA 209482 Orange Book
- First approved
- 09/18/2017 Orange Book
- Dosage forms
- powder
- Routes
- inhalation
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.